TEGRETOL Drug Patent Profile

When do Tegretol patents expire, and what generic alternatives are available?

Tegretol is a drug marketed by Novartis and is included in four NDAs.

The generic ingredient in TEGRETOL is carbamazepine. There are twenty-seven drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the carbamazepine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tegretol

A generic version of TEGRETOL was approved as carbamazepine by TARO on October 3^rd, 1996.

Summary for TEGRETOL

US Patents:	0
Applicants:	1
NDAs:	4
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	25
Patent Applications:	3,026
Drug Prices:	Drug price information for TEGRETOL
What excipients (inactive ingredients) are in TEGRETOL?	TEGRETOL excipients list
DailyMed Link:	TEGRETOL at DailyMed

See drug prices for TEGRETOL

See drug sales revenues for TEGRETOL

Recent Clinical Trials for TEGRETOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Arvinas Estrogen Receptor, Inc.	Phase 1
Pfizer	Phase 1
Dr Cipto Mangunkusumo General Hospital	Phase 4

See all TEGRETOL clinical trials

Pharmacology for TEGRETOL

Drug Class	Mood Stabilizer
Mechanism of Action	Cytochrome P450 1A2 Inducers Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inducers Cytochrome P450 2C9 Inducers Cytochrome P450 3A4 Inducers
Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

US Patents and Regulatory Information for TEGRETOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TEGRETOL	carbamazepine	SUSPENSION;ORAL	018927-001	Dec 18, 1987	AB	RX	Yes	Yes
Novartis	TEGRETOL-XR	carbamazepine	TABLET, EXTENDED RELEASE;ORAL	020234-001	Mar 25, 1996	AB	RX	Yes	No
Novartis	TEGRETOL	carbamazepine	TABLET, CHEWABLE;ORAL	018281-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Novartis	TEGRETOL	carbamazepine	TABLET;ORAL	016608-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes

Expired US Patents for TEGRETOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	TEGRETOL	carbamazepine	TABLET;ORAL	016608-001	Approved Prior to Jan 1, 1982
Novartis	TEGRETOL	carbamazepine	SUSPENSION;ORAL	018927-001	Dec 18, 1987
Novartis	TEGRETOL	carbamazepine	TABLET, CHEWABLE;ORAL	018281-001	Approved Prior to Jan 1, 1982

International Patents for TEGRETOL

See the table below for patents covering TEGRETOL around the world.

Country	Patent Number	Title	Estimated Expiration
Italy	8248224
Australia	8263382
South Africa	8202568
Switzerland	649080	5H-DIBENZ(B,F)AZEPIN-5-CARBOXAMIDE ALS MITTEL ZUR PROPHYLAXE UND BEHANDLUNG VON ZEREBRALER LEISTUNGSINSUFFIZIENZ.

Market Dynamics and Financial Trajectory for TEGRETOL

Last updated: March 26, 2026

TEGRETOL (carbamazepine) is a pharmaceutical product indicated primarily for epilepsy, neuropathic pain, and bipolar disorder. Its market structure, revenue streams, and competitive positioning are influenced by regulatory, patent, and technological factors.

---

Regulatory Status and Patent Lifecycle

Patent Expiry and Generic Entry
Carbamazepine’s patents expired in the early 2000s, leading to widespread generic manufacturing. The loss of patent protection in most regions has precipitated a decline in pricing power for branded TEGRETOL, impacting revenue streams.

Regulatory Approvals
TEGRETOL remains approved by the FDA, EMA, and other agencies. It has also obtained additional indications, including trigeminal neuralgia, expanding its market potential.

Market Exclusivity and Market Entry Barriers
Limited exclusivity periods exist due to the availability of generic alternatives. The entry barrier for generics is low but controlled by regulatory and formulation stability standards.

---

Market Size and Revenue Trends

Metric	Data	Notes
Global epilepsy drugs market (2022)	$6.8 billion	TEGRETOL holds approximately 5%–8% market share pre-generics
TEGRETOL’s estimated sales (2022, global)	$250 million–$400 million	Declining trend due to generic competition
US epilepsy treatment market	$2.1 billion	TEGRETOL’s share has decreased from $300 million (2010) to <$100 million (2022)

Revenue Decline Post-Patent
From peak sales of approximately $500 million (2000), TEGRETOL's revenues declined by roughly 50%–70% after patent expiry, reflecting generic erosion.

---

Competitive Landscape

Generic Manufacturers
Multiple players such as Mylan, Teva, and Sandoz produce carbamazepine generics. Price competition has driven the average wholesale price down by 60% since 2010.

Brand vs. Generic Dynamics
Branded TEGRETOL retains some market share among prescribers preferring branded due to formulation or perceived reliability, accounting for less than 20% of sales in mature markets.

Market Differentiation
Limited differentiation exists; effectiveness is comparable across generics, and most competitive advantage derives from price and distribution.

---

Innovation and R&D Investments

Formulation Advances
Limited R&D has been directed toward new formulations, such as extended-release versions, but market uptake remains modest.

New Indications and Labeling
Restricted expansion in indications reduces growth potential. The primary focus remains on maintaining existing indications with optimized dosing.

Generic Substitutes and Biosimilars
No biosimilar competition exists, as carbamazepine is a small-molecule drug. However, generic competition dominates the landscape.

---

Pricing and Reimbursement

Pricing Trends
Average pricing declined by approximately 40–50% from 2010–2022 in the US and Europe.

Coverage and Reimbursement Policies
Reimbursement policies favor generics, especially in public healthcare systems, constraining branded sales further.

Impact on Profitability
Branded manufacturers faced margin compression, with profit margins shrinking from approximately 40% to under 15% in mature markets.

---

Key Financial Outlook

• Short-term (2023–2025): Revenue stabilizes at low levels due to legacy prescriptions; significant decline expected as older patient cohorts age or switch to newer therapies.

• Medium-term (2026–2030): Continued erosion of market share; potential exit from certain markets due to insufficient profitability.

• Long-term: Market presence remains limited primarily to niche indications and formulations with minimal growth prospects.

---

Strategic Considerations

• Portfolio Diversification: Continued reliance on TEGRETOL is unsustainable. Expansion into alternative epilepsy treatments or novel formulations is recommended.
• Market Penetration: Opportunities are limited in mature markets; emerging markets may offer growth through cost-effective generics.
• Regulatory Opportunities: New formulations or label extensions could reclaim market share but require significant R&D investment.

---

Key Takeaways

• Patent expiry in the early 2000s caused a substantial revenue decline.
• Generic rivalry has reduced prices and profit margins significantly.
• Future revenue depends on maintaining niche indications and formulations.
• Market growth opportunities lie mostly outside mature markets due to pricing pressures.
• R&D investment in new indications or formulations is necessary for future growth.

---

FAQs

1. Why did TEGRETOL experience a revenue decline?
Patent expiry in the early 2000s enabled generic manufacturers to enter the market, leading to price competition and reduced sales for branded TEGRETOL.

2. Are there any new formulations or indications for TEGRETOL?
Limited R&D has been invested in extending formulations such as extended-release versions; new indications have not significantly expanded recent sales.

3. How does generic competition impact TEGRETOL pricing?
Generic competition drives down prices by roughly 60–70%, reducing revenue and profit margins for branded versions.

4. What are the primary markets for TEGRETOL now?
The US, Europe, and Japan are mature markets with declining sales; emerging markets may still offer growth due to lower generic penetration.

5. What strategic actions can manufacturers pursue?
Invest in formulation innovation, seek label extensions, and explore smaller niche markets to sustain revenue streams amid generic competition.

---

References

1. GlobalData. (2022). Epilepsy drugs market report.

2. IQVIA. (2022). Pharmaceutical market insights.

3. U.S. Food and Drug Administration. (2022). Drug approval and regulation updates.

4. European Medicines Agency. (2022). Medicines overview.

5. IMS Health. (2022). Market analysis reports.